Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Fosun and Sinopharm Form $1 Billion Drug Distribution JV

publication date: Jun 6, 2014
Shanghai Fosun High Technology and Sinopharm Group will form a JV to build a nationwide drug logistics network. The “early stage” investment is expected to total between $500 million and $1 billion. In China, there are no national-level drug-device distribution companies that can supply a product everywhere in the country. The Sinopharm-Fosun JV seems to be aimed at building that company. Fosun will own 60% of the JV and Sinopharm the remaining 40%. More details....

Stock Symbols: (HK: 656) (HK: 1099)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital